NCT02464046View on ClinicalTrials.gov

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 27, 2015

Primary Completion Date

December 2, 2015

Study Completion Date

December 2, 2015

Conditions
Insomnia
Interventions
DRUG

JNJ-42847922

Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.

DRUG

Placebo

Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.

Trial Locations (5)

Unknown

Hollywood

Berlin

Hamburg

Schwerin

Leiden

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02464046 - Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity | Biotech Hunter | Biotech Hunter